VIGL

Insider Trades

Name	Value	Action	Price	Current Price
Magovcevic-Liebisch IvanaDirector, Officer: President And CEO $12k5k shares BuyDec 5, 2024 $2.34 --
Magovcevic-Liebisch IvanaDirector, Officer: President And CEO $8.3k5k shares BuyDec 18, 2024 $1.67 --
Magovcevic-Liebisch IvanaDirector, Officer: President And CEO $8.4k5k shares BuyDec 19, 2024 $1.68 --
Budd Haeberlein Samantha L.Director $21k12k shares BuyDec 19, 2024 $1.71 --

Trade VIGL

About Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotechnology company concentrating on microglia to develop transformative treatments for neurodegenerative diseases. The firm aims to provide disease-altering therapies for patients, their families, and caregivers affected by both rare and widespread neurological disorders. The company's primary experimental therapy is VGL101, a fully human monoclonal antibody (mAb). This compound is engineered to activate the triggering receptor expressed on myeloid cells 2 (TREM2) and is currently in Phase I clinical trials. VGL101 is being investigated for its potential in treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy, and Alzheimer's disease. Furthermore, Vigil Neuroscience is also advancing an orally administered small molecule designed to act as a TREM2 agonist. This alternative therapeutic approach targets common neurodegenerative conditions associated with impaired microglial function.

CEO: Ivana Magovcevic-Liebisch
IPO Date: Jan 7, 2022

Market Data

Open: $8.05
High: $8.05
Low: $8.05
Volume: 5.5M
Avg Volume: 1.7M
52W High: $8.10
52W Low: $1.31

Valuation

Market Cap: $376M
Enterprise Value: $347M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-51M
Revenue: $0
Net Income: $-84M
Cash: $39M
Debt: $13M

Events

EarningsAug 5

EPS est. -0.43 · actual -0.55992